Significance of Up-Front Stereotactic Radiosurgery for Non–Small Cell Lung Cancer Patients With Brain Metastases in the Era of New Generation Tyrosine Kinase Inhibitors

Masamune Noguchi

Masamune Noguchi, MD, and Kenta Nimura, MD, Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Japan Department of Radiology, Nagoya University Graduate School of Medicine, Nagoya, Japan; and Yutaro Koide, MD, PhD, Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Japan

Yurika Shindo

Masamune Noguchi, MD and Yurika Shindo, MD, Department of Radiation Oncology, Aichi Cancer Center Hospital, Chikusa-ku, Nagoya, Japan; Kohei Wakabayashi, MD, Department of Radiation Oncology, Hamamatsu University School of Medicine, Hamamatsu, Japan; and Yutaro Koide, MD, PhD, Department of Radiation Oncology, Aichi Cancer Center Hospital, Chikusa-ku, Nagoya, Japan

Kohei Wakabayashi

Masamune Noguchi, MD and Yurika Shindo, MD, Department of Radiation Oncology, Aichi Cancer Center Hospital, Chikusa-ku, Nagoya, Japan; Kohei Wakabayashi, MD, Department of Radiation Oncology, Hamamatsu University School of Medicine, Hamamatsu, Japan; and Yutaro Koide, MD, PhD, Department of Radiation Oncology, Aichi Cancer Center Hospital, Chikusa-ku, Nagoya, Japan

Yutaro Koide